.avif)
Mirati Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
San Diego, CA, USA
Mirati Therapeutics is a biotechnology company focused on developing breakthrough therapies that target the genetic drivers of cancer, now part of Bristol Myers Squibb.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@mirati.com
Company Overview
Industry
Biotechnology Research
Founded
2013
Headquarters
San Diego, CA, USA
Revenue
$10M-$25M
FUNDING Stage
Acquired
Website
Key Executives
Charles M. Baum (President, Chief Executive Officer and Founder)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Mirati Therapeutics?
Mirati Therapeutics uses the firstinitiallast format on mirati.com, so Jane Smith would be jsmith@mirati.com.
What cancer indications is Mirati Therapeutics' KRAZATI approved to treat?
KRAZATI (adagrasib), developed by Mirati Therapeutics, received FDA accelerated approval in December 2022 for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, and in June 2024 in combination with cetuximab for KRAS G12C-mutated metastatic colorectal cancer.
Who founded Mirati Therapeutics and how long did he lead the company?
Charles M. Baum founded Mirati Therapeutics and served as President, CEO, and Board Member from 2012 until the company was acquired by Bristol Myers Squibb in January 2024, guiding it from a clinical-stage startup to a commercial-stage oncology company.
How can I find and verify a contact at Mirati Therapeutics for outreach?
Mirati Therapeutics follows the firstinitiallast@mirati.com email pattern, so you can build addresses if you know a contact's name. Tools like Clay can help you verify those addresses and enrich your prospect records with up-to-date details before reaching out.
Does Mirati Therapeutics have any partnerships for commercializing adagrasib outside the United States?
Mirati Therapeutics partnered with Zai Lab in 2021 to develop and commercialize adagrasib in Greater China, while retaining full and exclusive rights to the drug in all other countries outside that region.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating